Telomir Pharmaceuticals Inc (TELO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.78-10.85%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TELO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
TELO — private placement
Dated 2026-10-06
Entry into a Material Definitive Agreement. PIPE Financing On October 5, 2026, Telomir Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with various investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “ Private Placement ”) 4,843,300 shares (the “ Shares ”) of the Company’s common stock, no par value (the “ Common Stock ”). The securities sold to the…
Why it matters: The first trial stage tests safety, tolerability, and dose. Clear results would support moving to the efficacy stage.
Supportive ifThe company reports trial data that support a dose choice, with no safety issue that stops dosing.
Worry ifThe company reports a serious safety issue, pauses dosing, or cannot select a dose for the next stage.
Why it matters: The FDA-cleared trial is Telomir-Zn's main move from lab work to human testing. A start would show progress on its top goal.
Supportive ifThe company names its first patient dosed in the Phase 1/2 TNBC trial.
Worry ifA company update says trial site start or first dosing is delayed, or the trial is paused.
Why it matters: Telomir agreed to file for resale of the new shares. The filing and its timing will show when investors may resell them.
Worry ifThe SEC filing appears on time under the registration rights agreement and covers all 4,843,300 shares.
Less concerning ifThe company reports a missed or delayed filing deadline, or a filing that leaves out some of the 4,843,300 shares.
Why it matters: The dog cell tests are early lab results, not proof of benefit in animals. A planned live-animal study would be the next test.
Supportive ifTelomir names a start date, study plan, and partner for a study of bone cancer in a living dog.
Worry ifTelomir says it will not pursue the study, or gives no study plan in its next update on the program.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$239 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $588 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,764 loss on $10,000 · 47.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The October PIPE is meant to fund clinical work, but the company remains loss-making. Cash and spending updates will show how far funds may go.
Watch forThe report gives cash and trial spending details and says the $5.6 million PIPE supports planned TNBC work without a new share sale.
Also watch forThe report shows a fresh share sale, a stated cash shortfall, or a pause in planned TNBC work.